JP6417532B2 - 放出制御医薬剤形 - Google Patents

放出制御医薬剤形 Download PDF

Info

Publication number
JP6417532B2
JP6417532B2 JP2016500595A JP2016500595A JP6417532B2 JP 6417532 B2 JP6417532 B2 JP 6417532B2 JP 2016500595 A JP2016500595 A JP 2016500595A JP 2016500595 A JP2016500595 A JP 2016500595A JP 6417532 B2 JP6417532 B2 JP 6417532B2
Authority
JP
Japan
Prior art keywords
doxycycline
dosage form
controlled release
weight
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016500595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516031A5 (enExample
JP2016516031A (ja
Inventor
チャンドラン，サジーヴ
クルカルニ，シリシュクマール
メグラジ ブタダ，プラヴィン
メグラジ ブタダ，プラヴィン
アショクラオ デシュムク，アシシュ
アショクラオ デシュムク，アシシュ
ベイカン，ダグラス
ウォルツマン，ミッチェル
Original Assignee
メディシス ファーマシューティカル コーポレイション
メディシス ファーマシューティカル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディシス ファーマシューティカル コーポレイション, メディシス ファーマシューティカル コーポレイション filed Critical メディシス ファーマシューティカル コーポレイション
Publication of JP2016516031A publication Critical patent/JP2016516031A/ja
Publication of JP2016516031A5 publication Critical patent/JP2016516031A5/ja
Application granted granted Critical
Publication of JP6417532B2 publication Critical patent/JP6417532B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016500595A 2013-03-15 2014-03-04 放出制御医薬剤形 Active JP6417532B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN304/KOL/2013 2013-03-15
IN304KO2013 2013-03-15
US13/890,173 2013-05-08
US13/890,173 US10842802B2 (en) 2013-03-15 2013-05-08 Controlled release pharmaceutical dosage forms
PCT/US2014/020251 WO2014149674A1 (en) 2013-03-15 2014-03-04 Controlled release pharmaceutical dosage forms

Publications (3)

Publication Number Publication Date
JP2016516031A JP2016516031A (ja) 2016-06-02
JP2016516031A5 JP2016516031A5 (enExample) 2017-04-06
JP6417532B2 true JP6417532B2 (ja) 2018-11-07

Family

ID=54198667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500595A Active JP6417532B2 (ja) 2013-03-15 2014-03-04 放出制御医薬剤形

Country Status (8)

Country Link
US (1) US10842802B2 (enExample)
EP (1) EP2968179B1 (enExample)
JP (1) JP6417532B2 (enExample)
KR (1) KR102298473B1 (enExample)
CN (2) CN112007007A (enExample)
AU (1) AU2014237934B2 (enExample)
CA (1) CA2906378C (enExample)
WO (1) WO2014149674A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528983B2 (en) * 2014-05-12 2016-12-27 Anna Merritt Holmes Physicochemical modification and application of alginate gels for the controlled release of reagents in classical solution assays and microfluidic assays
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
WO2016079590A1 (en) 2014-11-19 2016-05-26 Dr. Reddy's Laboratories Ltd. Modified release doxycycline composition
ITUB20150279A1 (it) * 2015-03-09 2016-09-09 S I I T S R L Servizio Int Imballaggi Termosaldanti Sistema flottante per la cura dei sintomi delle affezioni gastriche
EP3996746A4 (en) * 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
ES2150017T3 (es) 1994-12-16 2000-11-16 Warner Lambert Co Proceso de encapsulacion de comprimidos en una capsula y formas de dosificacion solidas obtenidas por este proceso.
US6245350B1 (en) 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
JPH0995440A (ja) 1995-09-29 1997-04-08 Roussel Morishita Kk 徐放性製剤およびその製造方法
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
AU713276B2 (en) 1996-05-23 1999-11-25 Samyang Corporation Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
RU2193880C2 (ru) 1997-06-11 2002-12-10 Дзе Проктер Энд Гэмбл Компани Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта
AU747549B2 (en) 1998-03-23 2002-05-16 General Mills Inc. Encapsulation of components into edible products
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
DK1119345T3 (da) 1998-10-09 2009-08-03 Gen Mills Inc Indkapsling af fölsomme flydende bestanddele i en matrix til opnåelse af adskilte opbevaringsstabile partikler
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HK1044476B (zh) 1999-03-17 2010-09-17 第一制药株式会社 药物组合物
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
CA2395331C (en) 1999-12-23 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
CA2419434A1 (en) * 2000-09-19 2003-02-07 Daiichi Pharmaceutical Co., Ltd. Medicinal composition
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
IN192750B (enExample) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
WO2002083106A1 (en) 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
JP2005523309A (ja) 2001-12-20 2005-08-04 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法と製剤
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
WO2003075852A2 (en) 2002-03-07 2003-09-18 Advancis Pharmaceuticals Corporation Antibiotic composition
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
AUPS167602A0 (en) 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
JP2005523313A (ja) 2002-04-16 2005-08-04 コッラジェネックス ファーマシューチカルス インコーポレイテッド 目の酒さ及び酒さ性ざ瘡の同時治療方法
US8192749B2 (en) 2003-04-16 2012-06-05 Galderma Laboratories Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
AU2003243607A1 (en) 2002-06-20 2004-01-06 Royer Biomedical, Inc. Resorbable matrices with coatings for delivery of bioactive compounds
WO2004000363A1 (ja) 2002-06-25 2003-12-31 Takeda Pharmaceutical Company Limited 徐放性組成物の製造方法
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1417958A1 (en) 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
US7910128B2 (en) 2003-01-03 2011-03-22 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
CA2520321A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
ES2391385T3 (es) 2003-04-07 2012-11-23 Supernus Pharmaceuticals, Inc. Formulaciones de doxiciclinas en dosis única diaria
JP2006523703A (ja) 2003-04-14 2006-10-19 シャイア ラボラトリーズ，インコーポレイテッド 吸収ウィンドウ問題を克服するための、活性剤をバッカルまたは舌下の位置から放出する薬学的組成物
EP1638530A2 (en) 2003-06-20 2006-03-29 Royer Biomedical, INC. Drug polymer complexes
AU2004261143B2 (en) 2003-07-25 2009-11-05 Allergan Pharmaceuticals International Limited A doxycycline metal complex in a solid dosage form
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US20050049210A1 (en) 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
CA2543940A1 (en) 2003-10-27 2005-05-19 Dow Corning Corporation Preparations for topical application and methods of delivering an active agent to a substrate
WO2005046651A1 (en) 2003-11-12 2005-05-26 Ranbaxy Laboratories Limited Liquid filled capsules of doxycycline
JP2007513145A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
DE10358748A1 (de) 2003-12-12 2005-07-14 Lts Lohmann Therapie-Systeme Ag Darreichungsform basierend auf vernetzten hydrophilen Polymeren
US7410480B2 (en) 2004-04-21 2008-08-12 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
EP1758557B1 (en) 2004-05-11 2011-07-13 Egalet Ltd. Swellable dosage form comprising gellan gum
CN101005828B (zh) 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
US20080161273A1 (en) 2004-10-20 2008-07-03 Galderma Research & Development Method of Using Adapalene in Acne Maintenance Therapy
US8715724B2 (en) 2004-10-29 2014-05-06 Mayne Pharma International Pty Ltd Tabletting process
US20060147491A1 (en) 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
US9205047B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20100215744A1 (en) 2008-08-06 2010-08-26 Medicis Pharmaceutical Corporation Hydroxypropyl Substitution Used to Regulate Dissolution of a Chemical
WO2007036952A2 (en) 2005-07-01 2007-04-05 Rubicon Research Pvt Ltd. Novel sustained release dosage form
WO2007004236A2 (en) 2005-07-04 2007-01-11 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
RU2385712C2 (ru) 2005-08-24 2010-04-10 Рубикон Рисёч Пвт Лтд. Рецептура с контролируемым высвобождением
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007038867A1 (en) 2005-10-04 2007-04-12 Mistral Pharma Inc. Controlled-release oral dosage form
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
US9078811B2 (en) 2006-01-24 2015-07-14 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
EP2457563B1 (en) 2006-05-09 2017-03-22 Mallinckrodt LLC Zero-order modified release solid dosage forms
CA2655596C (en) 2006-06-27 2011-10-25 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
US20080014257A1 (en) 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
WO2008058288A2 (en) 2006-11-09 2008-05-15 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
DK2120963T3 (en) 2006-12-21 2019-01-14 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
GB0703627D0 (en) 2007-02-24 2007-04-04 Agt Sciences Ltd Aqueous formulations
WO2008104996A2 (en) 2007-02-28 2008-09-04 Jubilant Organosys Limited Water dispersible pharmaceutical formulation and process for preparing the same
AU2008231033B2 (en) 2007-03-23 2012-08-30 Molecular Research Center, Inc. Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy
EP2167036B1 (en) 2007-07-11 2013-09-18 Dow Corning Corporation Compositions for delivering a drug
CN101380474B (zh) 2007-09-06 2012-07-25 北京大学 用于口服制剂的pH敏感性固体药物组合物及制备方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
EP2133071A1 (en) 2008-06-09 2009-12-16 Université de la Méditerranée Process for making gastroretentive dosage forms
CA2730340C (en) 2008-07-14 2017-02-07 Polypid Ltd. Sustained-release drug carrier composition
WO2010017215A2 (en) 2008-08-04 2010-02-11 The Regents Of The University Of California Biodegradable microspheres and methods of use thereof
US20120028929A1 (en) 2008-09-19 2012-02-02 Alacrity Bioscience, Inc. Tetracycline stabilizing formulations
US10463623B2 (en) 2008-09-22 2019-11-05 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
DE102008048729A1 (de) 2008-09-24 2010-03-25 Add Technologies Ltd Advanced Drug Delivery Multipartikuläre Tabletten und Verfahren zur deren Herstellung
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
WO2010038234A1 (en) 2008-10-02 2010-04-08 Taro Pharmaceutical Industries Ltd. Combination product of spironolactone and doxycycline
EP2331209A1 (en) 2008-10-02 2011-06-15 Bayer Consumer Care AG Compositions for treating or alleviating skin diseases or disorders related to an enhanced level of anti-microbial peptides and proteins
WO2010066203A1 (en) 2008-12-10 2010-06-17 Anhui Zhongren Technology Co., Ltd. Controlled releasing composition
CA2746887C (en) 2008-12-15 2016-07-05 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
WO2010120892A2 (en) 2009-04-14 2010-10-21 The Regents Of The University Of California Improved oral drug devices and drug formulations
GB0907019D0 (en) 2009-04-24 2009-06-03 Oxford Nutrascience Ltd Pharmaceutical,therapeutic or nutritional delivery systems for functional ingredients
US20100291201A1 (en) 2009-05-14 2010-11-18 Cerovene, Inc. Coated pharmaceutical capsule dosage form
WO2010138837A2 (en) 2009-05-28 2010-12-02 Northwestern University Nanodiamond particle complexes
EP2485742A4 (en) 2009-10-06 2013-03-20 Scott Dorfner ANTIBIOTIC FORMULATIONS WITH REDUCED SIDE EFFECTS ON STOMACH AND DARM
ES2752008T3 (es) 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
US20120076742A1 (en) 2010-04-21 2012-03-29 Phillips D Howard Topical drug delivery system with dual carriers
CA2802041A1 (en) 2010-06-11 2011-12-15 Precision Dermatology, Inc. High oil-content emollient aerosol foam compositions
CN103228268A (zh) 2010-10-21 2013-07-31 高德美国际公司 缓释释放片剂及其制备方法
US8652516B1 (en) 2013-03-15 2014-02-18 Cerovene, Inc. Doxycycline formulations, and methods of treating rosacea

Also Published As

Publication number Publication date
AU2014237934B2 (en) 2019-01-24
EP2968179A4 (en) 2016-08-31
KR20160021074A (ko) 2016-02-24
CN105188683A (zh) 2015-12-23
CN112007007A (zh) 2020-12-01
US20140274970A1 (en) 2014-09-18
AU2014237934A1 (en) 2015-09-24
KR102298473B1 (ko) 2021-09-03
WO2014149674A1 (en) 2014-09-25
US10842802B2 (en) 2020-11-24
EP2968179B1 (en) 2019-11-06
EP2968179A1 (en) 2016-01-20
CA2906378A1 (en) 2014-09-25
CA2906378C (en) 2021-06-22
JP2016516031A (ja) 2016-06-02

Similar Documents

Publication Publication Date Title
JP6314188B2 (ja) トファシチニブの経口持続放出剤形
JP4827915B2 (ja) リファキシミンを含む胃抵抗性薬剤組成物
CN101636152B (zh) 含有西洛他唑的控释制剂及其制备方法
KR20090042967A (ko) 플리반세린 제형 및 이의 제조방법
WO2009084040A1 (en) Once a day formulation of angiotensin receptor blockers
JP6417532B2 (ja) 放出制御医薬剤形
WO2009047802A2 (en) Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
US20090004284A1 (en) Controlled release tamsulosin hydrochloride formulation
CN1178659C (zh) 控释活性化合物的药物制剂
WO2011077239A2 (en) Slow release pharmaceutical compositions of iloperidone
KR20060136409A (ko) 벤라팍신 히드로클로라이드의 방출연장형 코팅 미니정제
KR20070000439A (ko) 벤라팍신 히드로클로라이드의 방출연장형 코팅 미니정제
US9820936B2 (en) Oral controlled release pharmaceutical compositions of Bepotastine
US20100280035A1 (en) Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier
EP2685966A1 (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
EP2386302A1 (en) A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
JP5070618B2 (ja) 腸溶性顆粒剤及びその製造方法
HK40041911A (en) Controlled release pharmaceutical dosage forms
EP1897537A1 (en) Composition comprising an angiotensin II receptor antagonist
CN101784264A (zh) 用于延长释放的药物制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180625

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180906

R150 Certificate of patent or registration of utility model

Ref document number: 6417532

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250